stockrow
Monday 9 November 2026
Export IVF’s income statement to Excel — free account
INVO Fertility, Inc
IVFINVO Fertility, Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.8 million, up 4.74% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +100.1%
- Free cash flow
- +35.1%
- Total debt
- −50.7%
Quarter to June 2026, against a year earlier
2.14
0.11
+5.42%
Follow IVF
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 0 | 0 | 0 | 1 | 1 | 4 | 1 | 3 | 7 | 7 | 8 | +72.4% | 10 | 16 | 26 | +56.1% | |
| Gross margin, % | 70.33 | 81.60 | 81.72 | 90.97 | 91.44 | 96.51 | (3.48) | 35.96 | 44.00 | 36.96 | 35.28 | (33.4) pt | ||||||
| EBT | (2) | (1) | (3) | (2) | (8) | (7) | (11) | (8) | (8) | (5) | (7) | +11.1% | ||||||
| EBT margin, % | (4,173.48) | (248.92) | (622.19) | (146.41) | (804.71) | (159.86) | (1,324.45) | (265.07) | (116.35) | (80.19) | (93.55) | +4,093.3 pt | ||||||
| Net income | (2) | (1) | (3) | (2) | (8) | (7) | (11) | (8) | (9) | (23) | (7) | +30.5% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 8,780.92 | 5,186.50 | 10,400.25 | 2,055.50 | 3,020.60 | 2,598.25 | 58.47 | 3.58 | +274.9% | |||||
| Earnings | (0.02) | 0.00 | (0.02) | (12,858.26) | (43,797.89) | (18,153.07) | (25,932.96) | (7,390.90) | (3,782.65) | (214.64) | (44.30) | +188.9% | ||||||
| Cash flow | 0.00 | 0.00 | 0.00 | 8,130.15 | (23,875.50) | (15,074.75) | (16,508.25) | (4,755.10) | (1,183.13) | (59.95) | (2.26) | +209.5% | ||||||
| Capex | 0.00 | 0.00 | 0.00 | (680.43) | (445.00) | (1,136.50) | (31.75) | (444.70) | (43.00) | (0.37) | (0.02) | +149.2% | ||||||
| Free cash flow | 0.00 | 0.00 | 0.00 | 7,449.72 | (24,320.50) | (16,211.25) | (16,540.00) | (5,199.80) | (1,226.13) | (60.32) | (2.29) | +208.3% | ||||||
| Book value | (0.03) | (0.04) | (0.02) | (22,030.02) | 28,715.50 | 18,276.75 | (2,444.00) | 892.60 | 5,005.73 | 61.75 | 7.83 | n/m | ||||||
| Shares, m | 139 | 141 | 147 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | (54.5%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 883,505,236.93 | 69,243,011.43 | 115,368,949.17 | 26.92 | 66.85 | 9.22 | 6.15 | 5.31 | 3.54 | 0.81 | 0.60 | 106,811,731.6 | ||||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | 12.08 | 5.25 | 0.00 | 0.00 | 0.00 | 1.15 | 0.28 | 1.8 | ||||||
| EV/Sales | 883,505,236.72 | 69,243,011.84 | 115,368,949.44 | 26.34 | 57.69 | 8.37 | 9.28 | 6.34 | 4.41 | 0.63 | 0.19 | 106,811,731.1 | ||||||
| EV/FCF | (138,567,662.94) | (107,741,057.03) | (87,330,584.54) | 29.86 | (12.30) | (5.34) | (1.15) | (3.68) | (9.34) | (0.62) | (0.30) | (33,363,930.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | 0 | (1) | 1 | (5) | (6) | (7) | (5) | (3) | (7) | (5) | +40.7% | |||||
| Capex | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +12.0% | ||||||
| Free cash flow | 0 | 0 | (1) | 1 | (5) | (6) | (7) | (5) | (3) | (7) | (5) | +40.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | (5) | (5) | (3) | 0 | 8 | 5 | (3) | (7) | (17) | (8) | (2) | +5.9% | |||||
| Net debt | 0 | 0 | 0 | (1) | (10) | (4) | 2 | 1 | 1 | (1) | (3) | +70.9% | ||||||
| Shareholders’ equity | (5) | (5) | (3) | (4) | 6 | 7 | (1) | 1 | 13 | 7 | 16 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (490.60) | (254.14) | (589.46) | (168.49) | (131.01) | (62.16) | (153.67) | (72.33) | (29.45) | (75.81) | (38.79) | +414.8 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (92.43) | (1,102.70) | (220.95) | (31.64) | (76.78) | (27.92) | (76.8) pt | ||||||
| ROE | 50.73 | 14.61 | 79.73 | 67.34 | (822.60) | (101.96) | (343.99) | 264.08 | 83.06 | 387.43 | (203.65) | +336.7 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 3 | 1 | 2 | 5 | 10 | 12 | 14 | 30 | 32 | 42 | — | +34.1% | |||||
| Revenue/emp, $m | 0.02 | 0.28 | 0.25 | 0.30 | 0.10 | 0.35 | 0.06 | 0.10 | 0.20 | 0.16 | — | +28.6% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
INVO Fertility, Inc vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VVOS Vivos Therapeutics, Inc. | $3.2M | — (loss-making) | — (loss-making) | +34.90% (above 0%: growing) | n/m | +16.44% (above 0%: growing) | 57.31% | (93.63%) | Compare |
| AMIX Autonomix Medical, Inc. | $3.0M | — (loss-making) | — | — | n/m | −36.10% (below 0%: shrinking) | — | 0.00% | Compare |
| BJDX Bluejay Diagnostics, Inc. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | +20.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| AIDX 20/20 Biolabs Inc. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | −23.98% (below 0%: shrinking) | 41.71% | (170.30%) | Compare |
| IVF INVO Fertility, Inc | $2.6M | — (loss-making) | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | |
| NUWE Nuwellis, Inc. | $2.5M | — (loss-making) | — (loss-making) | +14.14% (above 0%: growing) | n/m | −51.55% (below 0%: shrinking) | 76.08% | (160.94%) | Compare |
| CODX Co-Diagnostics, Inc. | $2.4M | — (loss-making) | — (loss-making) | +1.96% (above 0%: growing) | n/m | +17.47% (above 0%: growing) | 72.73% | (3,733.17%) | Compare |
| ICCM IceCure Medical Ltd. | $2.3M | — (loss-making) | — (loss-making) | −0.69% (below 0%: shrinking) | n/m | +3.88% (above 0%: growing) | 32.38% | (466.19%) | Compare |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | — (loss-making) | — | — | n/m | −1.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $2.6M | — | — | +8.05% | — | +1.42% | 41.71% | (127.28%) |
Pay and ownership Proxy statement filed 23 June 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 430.86k | 389.58k | 0.03 |
| 2024 | 260.00k | 256.23k | 9.56 |
| 2023 | 232.68k | 202.08k | 15.93 |
Ownership
Directors and executive officers, together
0.43%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement